Long-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301 (EXIST-LT)
Latest Information Update: 12 Aug 2024
Price :
$35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Astrocytoma; Tuberous sclerosis
- Focus Therapeutic Use
- Acronyms EXIST-LT
- Sponsors Novartis
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 19 Jan 2024 This trial has been completed in Belgium (Global end date: 18 Dec 2023).
- 03 Dec 2021 Planned primary completion date changed from 25 Sep 2026 to 8 Jun 2026.